124 related articles for article (PubMed ID: 23487384)
21. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
[TBL] [Abstract][Full Text] [Related]
22. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
Pfaller MA
Am J Med; 2012 Jan; 125(1 Suppl):S3-13. PubMed ID: 22196207
[TBL] [Abstract][Full Text] [Related]
23. [Case of candidemia with Candida glabrata with confirmation of the acquisition of micafungin sensitivity due to new mutation of FKS gene mutation].
Saraya T; Watanabe T; Tsujimoto N; Takata S; Araki K; Makino H; Yonetani S; Takizawa H; Goto H
Kansenshogaku Zasshi; 2014 May; 88(3 Suppl 9-10):1-5. PubMed ID: 25033496
[No Abstract] [Full Text] [Related]
24. Caspofungin benefit on phagocytes from patients with renal dysfunction infected with multidrug-resistant Candida glabrata.
Banche G; Mandras N; Giacchino F; Scalas D; Allizond V; Roana J; Tullio V; Garneri G; Castagno F; Merlino C; Cuffini AM
Future Microbiol; 2013 Sep; 8(9):1091-6. PubMed ID: 23834733
[TBL] [Abstract][Full Text] [Related]
25. Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for
Wright WF; Bejou N; Shields RK; Marr K; McCarty TP; Pappas PG
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31345844
[TBL] [Abstract][Full Text] [Related]
26. Anidulafungin for Candida glabrata infective endocarditis.
De Rosa FG; D'Avolio A; Corcione S; Baietto L; Raviolo S; Centofanti P; Pasero D; Rinaldi M; Di Perri G
Antimicrob Agents Chemother; 2012 Aug; 56(8):4552-3. PubMed ID: 22644027
[No Abstract] [Full Text] [Related]
27. Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata.
Corcione S; D'Avolio A; Pasero D; Trentalange A; Pagani N; Sanguinetti M; De Rosa FG
Infez Med; 2019 Sep; 27(3):328-331. PubMed ID: 31545778
[TBL] [Abstract][Full Text] [Related]
28. Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study.
Biswas C; Chen SC; Halliday C; Kennedy K; Playford EG; Marriott DJ; Slavin MA; Sorrell TC; Sintchenko V
Clin Microbiol Infect; 2017 Sep; 23(9):676.e7-676.e10. PubMed ID: 28344162
[TBL] [Abstract][Full Text] [Related]
29. Caspofungin-non-susceptible Candida isolates in cancer patients.
Kofteridis DP; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2010 Feb; 65(2):293-5. PubMed ID: 20016020
[TBL] [Abstract][Full Text] [Related]
30. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
Borst A; Raimer MT; Warnock DW; Morrison CJ; Arthington-Skaggs BA
Antimicrob Agents Chemother; 2005 Feb; 49(2):783-7. PubMed ID: 15673768
[TBL] [Abstract][Full Text] [Related]
31. Tipping the balance both ways: drug resistance and virulence in Candida glabrata.
Vale-Silva LA; Sanglard D
FEMS Yeast Res; 2015 Jun; 15(4):fov025. PubMed ID: 25979690
[TBL] [Abstract][Full Text] [Related]
32. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
[TBL] [Abstract][Full Text] [Related]
33. Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.
Charlier C; El Sissy C; Bachelier-Bassi S; Scemla A; Quesne G; Sitterlé E; Legendre C; Lortholary O; Bougnoux ME
Antimicrob Agents Chemother; 2016 Jan; 60(1):662-5. PubMed ID: 26525799
[TBL] [Abstract][Full Text] [Related]
34. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
[TBL] [Abstract][Full Text] [Related]
35. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
36. Micafungin therapy in a critically ill, morbidly obese patient.
Zomp A; Bookstaver PB; Ahmed Y; Turner JE; King C
J Antimicrob Chemother; 2011 Nov; 66(11):2678-80. PubMed ID: 21810839
[No Abstract] [Full Text] [Related]
37. Caspofungin as treatment for Candida glabrata hip infection.
Lejko-Zupanc T; Mozina E; Vrevc F
Int J Antimicrob Agents; 2005 Mar; 25(3):273-4. PubMed ID: 15737527
[No Abstract] [Full Text] [Related]
38. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.
Gil-Alonso S; Jauregizar N; Ortega I; Eraso E; Suárez E; Quindós G
Int J Antimicrob Agents; 2016 Mar; 47(3):178-83. PubMed ID: 26857078
[TBL] [Abstract][Full Text] [Related]
39. Molecular Detection of Resistance to Echinocandins.
Posteraro B; Vella A; De Carolis E; Sanguinetti M
Methods Mol Biol; 2017; 1508():413-421. PubMed ID: 27837518
[TBL] [Abstract][Full Text] [Related]
40. In vivo Candida glabrata biofilm development on foreign bodies in a rat subcutaneous model.
Kucharíková S; Neirinck B; Sharma N; Vleugels J; Lagrou K; Van Dijck P
J Antimicrob Chemother; 2015 Mar; 70(3):846-56. PubMed ID: 25406296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
